SS-31 (Elamipretide) Research: What Published Studies Have Investigated

What is SS-31 (elamipretide)?

What is SS-31? It is a synthetic, water-soluble, mitochondria-targeting aromatic-cationic tetrapeptide of four residues (D-Arg-Dmt-Lys-Phe-NH₂), one of the Szeto–Schiller (SS) peptides. It is also known by the development names elamipretide, Bendavia, and MTP-131. The compound was first characterised by Hazel Szeto and colleagues at Weill Cornell, and the literature reports that it concentrates in the inner mitochondrial membrane independent of membrane potential — a property researchers have highlighted because most mitochondria-targeting molecules depend on that potential to accumulate. That is a neutral molecular definition; the sections below describe what researchers examined, not effects in people.

Molecule properties

SS-31 is a tetrapeptide of four amino acids with an aromatic-cationic, amphipathic structure. In research catalogues it is supplied as a synthetic lyophilized powder. It is catalogued as a research peptide, while the same molecule advanced through clinical development under the investigational-drug name elamipretide — the SS-31 and elamipretide designations refer to the identical tetrapeptide viewed from the research-reagent side and the drug-development side respectively. The aromatic-cationic design is what the literature ties to its membrane affinity: alternating aromatic and basic residues give the peptide the amphipathic character described in the Szeto reviews. These are molecule and naming facts only, with no handling or reconstitution instructions.

Mechanisms researchers have examined

The SS-31 mechanism literature centres on interactions with the inner mitochondrial membrane. Each direction below is framed as what researchers examined:

• Cardiolipin binding at the inner mitochondrial membrane — Birk et al. (2013, J Am Soc Nephrol, PMID 23813215) reported that SS-31 selectively associates with cardiolipin, the signature anionic phospholipid of the inner mitochondrial membrane.
• Stabilising the cytochrome c / cardiolipin interaction — studies examined whether cardiolipin binding limits cytochrome c peroxidase activity and helps keep cytochrome c anchored, a factor studied in electron-transport efficiency. Szeto (2014, Br J Pharmacol, PMID 24117165) reviewed this “cardiolipin-protective” framing.
• Cristae architecture and electron-transport efficiency — preclinical models examined effects on inner-membrane (cristae) morphology and mitochondrial bioenergetics under stress.
• Reactive-oxygen-species handling — studies investigated electron leak and superoxide generation at the electron-transport chain in ischemia and stress models.

The section closes as the literature does: SS-31 is described as a membrane-interacting mitochondrial peptide, with mechanisms characterised primarily in cell and animal models and clinical trials probing whether these translate. Importantly, no single confirmed downstream outcome follows from the cardiolipin interaction; the pathways above are reported as what was studied, and a mechanism observed in isolated mitochondria or cultured cells cannot establish a result in a person. Each bullet names a pathway examined, not an effect a reader would obtain.

Research models and clinical trials in the literature

On the preclinical side, ischemia-reperfusion and renal models (Birk 2013), a broad bioenergetics review (Szeto 2014), and Barth-syndrome cardiac models dominate the record. The distinguishing point — unusual for a research peptide — is that the same molecule, as elamipretide, was carried into registered human clinical trials by Stealth BioTherapeutics. Reported neutrally, as what each trial investigated and its published outcome, the picture is mixed. In primary mitochondrial myopathy (the MMPOWER programme), a dose-escalation phase 1/2 study (Karaa et al. 2018, Neurology, PMID 29500292) and a crossover MMPOWER-2 study (Karaa et al. 2020, J Cachexia Sarcopenia Muscle) were followed by the pivotal phase 3 MMPOWER-3 (Karaa et al. 2023, Neurology), which did not meet its primary endpoints (six-minute walk test and fatigue score).

In Barth syndrome, the phase 2/3 crossover TAZPOWER trial (Thompson et al. 2021, Genetics in Medicine) had a randomized part that did not meet its primary endpoints, followed by a 168-week open-label extension (Thompson et al. 2024, Genetics in Medicine, PMID 38602181). Additional registered trials have investigated dry age-related macular degeneration and heart failure, extending the programme beyond the mitochondrial-disease indications above. The value of reading these reports neutrally is that a registered trial documents a hypothesis a sponsor set out to test and the endpoint by which they agreed to judge it; when an endpoint is not met, that is itself a published finding, not a footnote to be reframed as success. Stated plainly: the human evidence is mixed and several pivotal endpoints were not met, so these trials describe what was investigated rather than an established benefit, and none of it means a reader would experience any effect.

SS-31 among mitochondria-targeting research peptides

Within the mitochondria-targeting research group, SS-31 is often set beside MOTS-c as a research-focus contrast rather than a ranking. SS-31 is a synthetic membrane-interacting tetrapeptide whose examined mechanism turns on binding cardiolipin at the inner mitochondrial membrane, whereas MOTS-c is a mitochondrially encoded signalling peptide studied along different pathways — the two are pursued as separate mechanistic questions. That distinction is what defines SS-31 as a research target: a membrane-interacting molecule with a specific phospholipid partner. Both are studied largely in preclinical settings, which is why they are so often discussed together, yet the mechanistic questions asked of each are distinct rather than interchangeable. For adjacent mitochondrial and redox research reagents catalogued in the same family, see methylene blue research and NAD research. This page hands off to those siblings rather than rebuilding their detail.

Research-grade sourcing and verification

For laboratory research use only, SS-31 is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation at the lot level. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. This is sourcing and identity-assurance framing only, not a statement about outcomes.

Frequently asked questions

Literature cited

1. Birk AV, Liu S, Soong Y, et al. “The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin.” J Am Soc Nephrol. 2013;24(8):1250–1261. PMID 23813215.
2. Szeto HH. “First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.” Br J Pharmacol. 2014;171(8):2029–2050. PMID 24117165.
3. Karaa A, Haas R, Goldstein A, et al. “Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy (MMPOWER).” Neurology. 2018;90(14):e1212–e1221. PMID 29500292.
4. Karaa A, Haas R, Goldstein A, et al. “A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy (MMPOWER-2).” J Cachexia Sarcopenia Muscle. 2020;11(4):909–918. doi:10.1002/jcsm.12559.
5. Karaa A, Bertini E, Carelli V, et al. “Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.” Neurology. 2023 (PMC10382259). Did not meet primary endpoints (6MWT, fatigue score).
6. Thompson WR, Manuel R, Abbruscato A, et al. “A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome (TAZPOWER).” Genetics in Medicine. 2021;23(3):471–478. doi:10.1038/s41436-020-01006-8. Randomized part did not meet primary endpoints.
7. Thompson WR, et al. “Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.” Genetics in Medicine. 2024;26(7):101138. PMID 38602181.